Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis

Annalisa Capuano¹, Emilio Clementi² and Giuseppe Paolisso³,*

¹Department of Experimental Medicine, University of Campania ‘Luigi Vanvitelli’, Naples, Italy, 
²Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy, 
³Department of Advanced Medical and Clinical Science, University of Campania ‘Luigi Vanvitelli’, Naples, Italy, 
*Mediterranea Cardiocentro, Naples, Italy

KEYWORDS
atherosclerosis, SGLT2 inhibitors, cardiovascular diseases, acute myocardial infarction, heart failure, peripheral artery diseases

Introduction

SGLT2 inhibitors have recently come to prominence in research due to their anti-atherosclerotic effect. This collection of articles highlights that these effects can be expressed both at the cardiovascular and cerebrovascular levels with a reduction in the risk of such events (1). Also of significant interest are the data showing that SGLT2 inhibitors can have an anti-arrhythmic effect, a finding that confirms previous in vivo experimental evidence in animals (2). The well-known beneficial effect of SGLT2 inhibitor administration on renal function could explain the highlighted data of a lower incidence of contrast medium side effects during revascularization procedures in acute myocardial infarction (AMI) patients (3). The molecular mechanisms related to the anti-atherosclerotic effect of SGLT2 are very complex and can range from molecular to clinical effects.

Molecular mechanisms for atherosclerosis

Atherosclerosis is a vascular disorder characterized by lipid particles, immune cells, and an extracellular matrix complex, which allows the development of plaques in the arterial wall. Such plaques may undergo erosion or rupture, being the cause of several cardiovascular diseases (CVD), encompassing AMI, stroke, heart failure (HF), and peripheral arterial disease. Genetic factors and continuous exposition to oxidative stress are additional factors that could be taken into account to explain the genesis and development of atherosclerosis. Furthermore, modifiable risk factors such as obesity,
diabetes mellitus, dyslipidemia, cigarette smoking, physical inactivity, and hypertension contribute further (4).

Once the initial lesions occur, the first stage comprises the endothelial dysfunction associated with disturbed shear stress, combined with a chronic inflammation state, changes in endothelial permeability, and infiltration of monocytes in the intimal layer. Oxidized-LDL can be responsible for damage-associated molecular patterns secretion that initializes an innate immune response by Toll-like receptors (TLR). As a result, an immune response develops, since vascular cell adhesion molecule 1 (VCAM-1) is expressed by endothelial cells, which recall other immunogenetic cells such as monocytes and leukocytes (4, 5). Monocytes transform themselves into activated M1 and M2 macrophages. The balance between the pro-inflammatory capacity of M1 and the anti-inflammatory propriety of M2 might be responsible for inflammation's occurrence or disappearance (4). A unique role also seems to be played by the lipids whose accumulation is associated with the appearance of foam cells and activation of nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome complex, which per se promotes the release of pro-inflammatory cytokines, contributing to the development of atherosclerotic plaque (5–7).

Oxidative stress and cellular senescence may contribute further to endothelial dysfunction and atherosclerosis. Reactive oxygen species (ROS) prompt the synthesis of pro-inflammatory cytokines, thus stimulating the expression of adhesion molecules, allowing monocytes to transmigrate into the vessel wall. On the other hand, ROS can favor scavenger receptors’ expression on vascular smooth muscle cells, which is responsible for lipid accumulation and switch in foam cells (4).

At the end of the atherosclerotic process, we can distinguish between two different plaques: i) stable plaques made up of a thick fibrous cap, which can regress with an appropriate lifestyle and/or drug therapy or may occlude the vessel lumen; ii) vulnerable or unstable plaques very rich in macrophages made up by a thick lipid core and a thin fibrous cap, which very often proceeds toward rupture and complication such as AMI and stroke (8–10).

Which role for SGLT2 inhibitors on cardiovascular diseases?

SGLT2 inhibitors display advantageous cardiac effects independent of the well-known anti-hyperglycemic effect. In particular, SGLT2 inhibitors reduce the occurrence of heart failure with reduced ejection fraction (HFrEF). This phenomenon is independent of glucose-metabolic control and attributable to both indirect and direct cardiac effects (9, 10). Recent studies have highlighted that SGLT2 inhibitors exerted their cardiovascular protective activity through hemodynamic effects (mainly related to an increased diuresis/natriuresis and decline in arterial blood pressure) and metabolic impact (9–12).

Do SGLT2 inhibitors play a role as anti-atherosclerotic drugs?

The potential anti-atherosclerotic role of SGLT2 inhibitors might be due to multifactorial effects related to a downgrade of inflammatory molecule secretion, reduction of macrophage infiltration, improvement in autophagy impairment, and opposition to endothelial dysfunction. To date, we can distinguish between glucose-dependent and independent anti-atherosclerotic effects. SGLT2 inhibitors, by decreasing plasma glucose levels, may decline macrophage inflammatory response since macrophages preferentially utilize glucose as an energy source. Such a hypothesis is strengthened by a positive linear correlation between neutrophil plasma levels measured at 24 h from AMI and admission plasma glucose levels or plasma troponin levels in AMI type 2 diabetic patients treated by SGLT2 inhibitors (13). Such data supported the hypothesis that such an anti-inflammatory effect might be attributed to tighter metabolic control of stress hyperglycemia independently of glucose control measured by HbA1c levels. As far as the glucose-independent anti-atherosclerotic process is concerned, recent studies have shown that empagliflozin might inhibit per se the nucleotide-binding domain-like receptor protein 3 inflammasome (NLRP3). Furthermore, dapagliflozin reduced the maturation and secretion of inflammatory markers (13), an effect associated with ketone inhibition of the NLRP3 (4). Indeed, SGLT2 inhibitors increase plasma beta-hydroxybutyrate with a parallel decline in fasting plasma insulin levels and a consequent rise in insulin sensitivity (13), all such activities correlated to the inhibition in NLRP3.

Clinical evidence for the anti-atherosclerotic role of SGLT2 inhibitors

Several recent studies have highlighted the anti-atherosclerotic role of SGLT2 inhibitors. In particular, the Real Catalonia study evidenced in heart failure patients with type 2 diabetes indicated that canagliflozin administration significantly lowered inflammatory biomarkers after 3, 6, and 12 months (14). In addition, the DEFENSE study demonstrated that dapagliflozin improved endothelial dysfunction in patients affected by type 2 diabetes mellitus (15). The sub-analyses of the CVD-REAL and CVD-REAL2
studies highlighted a reduced risk of AMI associated with SGLT2 inhibitors (16). As recently reported, three further studies (EMMY, DAPA-MI, and EMPACT-MI) confirm these data (16-19).

Conclusions

SGLT2 inhibitors may play an anti-atherosclerotic role through a well-defined anti-inflammatory role, which could be related to prevention in endothelial dysfunction and a reduced risk of AMI in type 2 diabetic patients.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

References

1. Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity. Data from basic science and clinical trials. Front Cardiovasc Med. (2022) 9:1008922. doi: 10.3389/fcvm.2022.10

2. Cesaro A, Gragnano F, Paolillo P, Bergamaschi L, Gallinoro E, Sardu C, et al. In-hospital arithmetical burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-1 AMI PROTECT study. Front Cardiovasc Med. (2022) 9:1012220. doi: 10.3389/fcvm.2022.1012220

3. Hua R, Ding N, Guo H, Wu Y, Yuan Z, Li T. Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis. Front Cardiovasc Med. (2022) 9:198167. doi: 10.3389/fcvm.2022.918167

4. Poyznyak A, Grechko AV, Poggi P, Myasadesova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. (2020) 21:1835. doi: 10.3390/ijms21051835

5. Rothen AE, Memish GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. (2022) 76:2982-3021.

6. Paolillo P, Foa A, Bergamaschi L, Donati F, Fabrizio M, Chiti C, et al. Hypermastigemia, inflammatory response and infarct size in obstructive acute myocardial infarction and MINOCA. Cardiovasc Diabetol. (2021) 20:33. doi: 10.1186/s12933-021-01222-9

7. Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. (2020) 41:2313–30. doi: 10.1093/eurheartj/ehaa962

8. Tomanaki M, Katagiri Y, Modolo R, de Silva R, Khamis RY, Bourantas CV, et al. Vulnerable plaques and patients: state-of-the-art. Eur Heart J. (2020) 41:2997–3004. doi: 10.1093/eurheartj/ehaa227

9. Sardu C, Modugno P, Castellano G, Scisciola L, Barbieri M, Petrella L, et al. Atherosclerotic plaque fissuration and clinical outcomes in pre-diabetics vs. normoglycemics patients affected by asymptomatic significant carotid artery stenosis at 2 years of follow-up: role of microRNAs modulation. The ATIMIR study. Biomedicines. (2021) 9:401. doi: 10.3390/biomedicines9040401

10. Marfella R, Scisciola L, D’Onofrio N, Maiello T, Trotta MC, Sardu C, et al. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes. Pharmacol Res. (2022) 184:106448. doi: 10.1016/j.phrs.2022.106448

11. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohn M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. doi: 10.1093/eurheartj/ehab368

12. Mascolo A, Scavone C, Scisciola L, Chiandini P, Capuano A, Paolillo G. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies. Pharmacol Res. (2021) 172:105836. doi: 10.1016/j.phrs.2021.105836

13. Paolillo P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. (2021) 21:77. doi: 10.1186/s12933-022-01506-8

14. Real J, Vlacho B, Ortega E, Valles JA, Mata-Cases M, Castelblanco E, et al. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol. (2021) 20:139. doi: 10.1186/s12933-021-01532-5

15. Shugyama F, Kumashiro N, Miyagi M, Rekara K, Kanda E, Uchino H, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus. DEFENCE study. Cardiovasc Diabetol. (2017) 16:84. doi: 10.1186/s12933-017-0564-0

16. Von Lewinski D, Kolesnik E, Trippol NJ, P尔斯chky PN, Benedikt M, Wällner M, et al. Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: IACC review topic of the week. J Am Coll Cardiol. (2022) 79:2058-68. doi: 10.1016/j.jacc.2022.03.353

17. von Lewinski D, Kolesnik E, Trippol NJ, P尔斯chky PN, Benedikt M, Wällner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. (2022) 43:4411–32. doi: 10.1093/eurheartj/ehac494

18. Zhu Y, Zhang JL, Yan XJ, Sun L, Ji Y, Wang FF. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol. (2022) 21:186. doi: 10.1186/s12933-022-01627-0

19. Harrington J, UdeIJA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Empagliflozin in patients post-myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. (2022) 253:86–98. doi: 10.1016/j.ahj.2022.05.010